Antigen binding proteins that bind c-met
There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.
1. A fully human anti-c-Met antibody of an IgG class comprising a heavy chain variable domain comprising all of the complementarity determining regions (CDRs) of a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable domain comprising all of the CDRs of a light chain comprising the amino acid sequence of SEQ ID NO: 20.
2. The fully human anti-c-Met antibody of claim 1 , wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 19 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 20.
3. A fully human anti-c-Met antibody Fab fragment comprising a heavy chain variable domain comprising all of the complementarity determining regions (CDRs) of a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable domain comprising all of the CDRs of a light chain comprising the amino acid sequence of SEQ ID NO: 20.
4. The fully human anti-c-Met antibody Fab fragment of claim 3 , wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 19 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 20.
5. A single chain anti-c-Met antibody comprising a heavy chain variable domain comprising all of the complementarity determining regions (CDRs) of a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain variable domain comprising all of the CDRs of a light chain comprising the amino acid sequence of SEQ ID NO: 20.
6. The single chain anti-c-Met antibody of claim 5 , wherein the heavy chain variable domain comprises the amino acid sequence of SEQ ID NO: 19 and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 20.